Cipla doubles Remdesivir production to meet 'unprecedented' demand

13 Apr 2021 Evaluate

Cipla has doubled production of COVID-19 medication remdesivir to help meet ‘unprecedented demand’ as the country battles a massive second wave of infections. India has overtaken Brazil as the world’s second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1369.55 -8.30 (-0.60%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×